View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
DOT/OST RIN: 2105-AF26 Publication ID: Spring 2024 
Title: ●Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Adding and Removing of Certain Schedule II Drugs to the Department of Transportation's Drug Testing Panel 
Abstract:

This rulemaking would adopt the drug testing panel identified by the U.S. Department of Health and Human Services (HHS) in their urine and oral fluid Mandatory Guidelines for Federal Workplace Drug Testing Programs by proposing to amend the Department of Transportation's Drug Testing Panel in 49 CFR Part 40 by adding Fentanyl and norfentanyl (Schedule II drugs) and removing Methylenedioxyamphetamine (MDA) and Methylenedioxymethamphetamine (MDMA).

 
Agency: Department of Transportation(DOT)  Priority: Substantive, Nonsignificant 
RIN Status: First time published in the Unified Agenda Agenda Stage of Rulemaking: Long-Term Actions 
Major: No  Unfunded Mandates: No 
CFR Citation: 49 CFR 40   
Legal Authority: Not Yet Determined   
Legal Deadline:  None
Timetable:
Action Date FR Cite
Next Action Undetermined  To Be Determined 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
RIN Information URL: www.regulations.gov   Public Comment URL: www.regulations.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Bohdan Baczara
Department of Transportation
Office of the Secretary
1200 New Jersey Avenue SE,
Washington, DC 20590
Phone:202 366-6364
Fax:202 366-3897
Email: bohdan.baczara@dot.gov